Street View: Thermo Fisher benefits from biopharma recovery, China momentum

By Reuters News

** Thermo Fisher TMO.N beat analyst estimates for third-quarter results on Wednesday, banking on strong demand for its life sciences tools, as biotech companies increase spending on research and manufacturing

** On average, 26 analysts rate the TMO stock at "buy"; their median PT is $735 - data compiled by LSEG


BROADER LIFE-SCIENCES MARKET RECOVERY

** William Blair ("outperform") says there were enough positive data points to support the market recovery thesis

** Evercore ("outperform", PT: $720) says the biotech market is improving, with customers expecting research-reagent spending to increase over the next couple of quarters

** Leerink Partners ("outperform", PT: $735) says "TMO is well positioned to deliver at the upper end of the 3%-6% organic growth framework."

** RBC Capital Markets ("sector perform", PT: $730) says TMO's China revenue accelerated to low-double-digit growth which is an encouraging indication that biopharma-led recovery is gaining traction

** Jefferies ("buy", PT: $785) says TMO's contract drug manufacturing business posted significant growth, though part of the increase reflected work originally scheduled for Q4 that was completed earlier in Q3

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.